Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease

Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaRecruiting - verified March 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials